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Abstract 
 
Parkinson’s disease (PD) is a progressive 
neurodegenerative disease caused by the death of 
midbrain dopaminergic neurons. The misfolding and 
aggregation of a membrane phospholipid binding 
protein, -synuclein, and the accumulation of oxygen 
radicals play a ruinous role in this selective cell death. 
How the protein’s aggregation and phospholipid binding 
properties contribute to its toxic nature is still unclear. 
To better understand -synuclein’s toxic mechanism, 
our lab previously developed comparative models in 
fission yeast and budding yeast. Using the model 
organisms, my thesis explored three related questions. 
First, I tested the hypothesis that -synuclein 
aggregation follows the nucleation polymerization 
theory, which requires that aggregates increase with 
concentration and over time. I analyzed -synuclein 
aggregation properties when it is expressed at moderate 
levels and compared my data with published work with 
high and low levels of -synuclein expression (Brandis 
et al. 2006). I found that moderately expressed -
synuclein formed fewer and later aggregates compared 
with highly expressed -synuclein, indicating a 
threshold concentration of -synuclein was critical for 
aggregation process. Together, both the published 
(Brandis et al., 2006) and the current thesis studies 
provide strong live cell support for the nucleation 
polymerization model. In my second study, I tested the 
hypothesis that increasing phospholipid association of 
-synuclein would enhance cellular toxicity of the 
protein. Using a chemical approach, I induced 
phospholipid synthesis of both fission yeast and 
budding yeast with dimethyl sulfoxide (DMSO), a known 
inducer (Murata et al., 2003). Instead of demonstrating -
synuclein-dependent toxicity, DMSO exerted an 
unexpected -synuclein-independent toxicity in both 
yeasts, in addition to inducing a lethal morphology 
defect in budding yeast. Moreover, instead of inducing 
plasma membrane localization of -synuclein in either 
yeast, DMSO altered -synuclein localization in both 
yeasts into as-yet unidentified cytoplasmic structures. 
We speculate that some of these structures may be 
internal membrane bound organelles. To test for 
membrane phospholipid binding specificity, -synuclein 
localization was analyzed in a phosphatidylserine-
deficient budding yeast strain. We observed no loss of 
plasma membrane localization suggesting that other 
phospholipids may regulate such specificity to -
synuclein. Lastly, I tested the hypothesis that -
synuclein toxicity will enhance in a combinatorial 
manner with oxidative stress in fission yeast, which has 
been an organism resistant to -synuclein’s toxicity. In 
my preliminary results, I have instead found an 
unexpected -synuclein-independent toxicity to the 
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oxidant, hydrogen peroxide. These related studies, 
together, illustrate the usefulness of yeasts in 
evaluating genetic and environmental factors that 
regulate -synuclein toxicity linked to PD. 
 
Introduction 
 
Neurodegenerative diseases are characterized by the 
progressive loss of function and death of neurons located in 
the central nervous system. These illnesses most of the time 
strike humans as they age. Some examples of 
neurodegenerative diseases include Alzheimer's disease, 
Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS; 
also known as Lou Gehrig's disease), Huntington’s disease, 
and Multiple Sclerosis (MS).  These disorders have genetic, 
sporadic (most common) and infectious (less common) 
causes. Pathologically, these diseases have some 
commonalities. When a neurodegenerative disease afflicts a 
human being, it leads to death of specific set of neurons 
within the brain.  For example in Huntington’s disease, the 
degeneration of neuronal cells occurs particularly in the 
caudate nucleus and putamen of the basal ganglia 
responsible for motor function, creating symptoms of jerky 
uncontrolled movement (Brown et al., 1999). 
Another common pathological feature that has 
been observed in these neurodegenerative diseases is the 
accumulation of abnormally folding protein into insoluble 
clumps. The protein aggregates either inside cytoplasm or 
extracellularly of dying neurons. The mechanism of protein 
misfolding and aggregating in relation to neuronal death is 
not clearly known (Ross and Poirier, 2004). The misfolding 
protein can arise from a mutation in the gene that transcribes 
it, or sporadic events with no known causes.    
 
Parkinson’s Disease  
Parkinson's disease (PD) is a progressive 
neurodegenerative movement disorder.  Classical symptoms 
include tremors, rigidity, slowness in movement, and poor 
balance and coordination. Most cases of PD are idiopathic, 
with unknown causes, and occur during late ages 
(http://www.nlm.nih.gov/medlineplus/parkinsonsdisease.html
). Approximately 10% of PD cases are known to be 
genetically linked (Eriksen et al., 2003).  The disease is fatal 
with no cure in sight, but over the last thirty years, varieties 
of drugs have been developed to cope with the symptoms.  
The manifestation of Parkinson’s disease occurs 
due to the death of dopaminergic neurons in the substantia 
nigra pars compacta (Figure 1). The pathogenic 
mechanisms for sporadic cases of PD are thought to involve 
mitochondrial impairment and oxidative stress (Chua and 
Tang, 2006) which can arise from exposure to pesticides, 
rural living, farming, and drinking well water (Jenner P, 2001; 
Sherer et al., 2002).  Moreover, when post mortem PD 
brains are examined, cytosolic inclusions called Lewy bodies 
appear as the prominent feature of this disease (Lücking, 
and Brice, 2000). 
Presently, key findings in PD research point to the 
hypothesis that the misfolded protein -synuclein plays a 
critical role in the pathogenesis. First, the Lewy bodies in the 
dying neurons contain a fibrillar form of misfolded -
synuclein (Spillantini et al., 1997). Also, three missense 
mutations in the -synuclein gene were discovered as a 
cause of autosomal dominantly inherited PD. Alanine at 53
rd
 
codon is replaced with threonine (A53T) in an Italian-
American  Greek family  (Polymeropoulos et al., 1997). Also,  
 
 
 
 
 
Figure 1. Manifestation of Parkinson’s disease from its 
pathology to its symptoms. The symptoms of Parkinson's disease 
result from the loss of dopaminergic cells in the ventral region of the 
substantia nigra. Because these neurons project to the striatum, their 
loss means changes in the activity of the neural circuits within the 
basal ganglia which regulate movement. In essence, there is an 
increase in inhibitory signal out of substantia nigra (denoted by red 
star), enventually leading to excitatory signal to the motor cortex and 
lower motor neurons which cause  a hypokinetic movement condition 
in PD.  
 
alanine at 30
th
 condon is replaced with proline in a German 
family (Kruger et al., 1998). Lastly, glutamic acid at 46
th
 
codon is replaced with lysine in a Spanish family (Zarranz et 
al., 2004).  
The normal function of -synuclein is still clearly 
not understood. -Synuclein is a natively unfolded protein 
composed of 140 amino acid residues (Kaplan et al., 2003). 
It is localized mainly at the presynaptic terminals shown by 
immunocytochemical and subcellular fractionation studies 
(Maroteaux et al., 1988). The expression of this protein is 
high with ongoing synaptic activity in the brain regions such 
as olfactory bulb, cerebral cortex, hippocampus and 
substantia nigra (Kaplan et al., 2003). Because -synuclein 
is present in the presynaptic neurons, many believe it is 
important in neuronal plasticity (Clayton and George, 1999), 
regulating neurotransmitter release, and neuronal 
differentiation (Lücking, and Brice, 2000).  
Using model organisms, transgenic mice (Masliah 
et al., 2000), and flies (Feany and Bender, 2000) carrying 
the human form -synuclein have been shown to generate 
Parkinsonian phenotypes; specific dopaminergic neurons 
degenerate, the -synuclein forms clumps, and the motor 
deficits are exhibited (Rochet et al., 2004). Besides the 
mutations in -synuclein, there are five other genes known to 
cause familial PD: parkin (Kitada et al., 1998), DJ-1 (Bonifati 
et al., 2003), ubiquitin carboxyl-terminal esterase L1 
(UCHL1—Funayama et al., 2002), phosphatase and tensin 
homologue (PTEN)-induced kinase 1 (PINK1—Valente et 
al., 2004), and leucine-rich repeat kinase 2 (LRRK2—
Paisan-Ruiz et al., 2004). Interestingly, while mutations in 
other genes result in functionally impaired or inactive protein 
products, studies of -synuclein show mutant -synuclein 
expression leads to a gain in function of the protein (Eriksen 
et al., 2003). The substantia nigral dopaminergic neurons of 
adult rat are selectively vulnerable to high levels of either 
wild-type or A53T mutated human -synuclein (Kaplan et al., 
2003). In contrast, the loss of -synuclein appears to have 
minimal effects. When -synuclein was knocked out in mice, 
the organism developed normally similar to wild-type 
(Abeliovich et al., 2000). Besides the use of animal models 
for research on PD, budding yeast has also been used to 
study the pathological properties of -synuclein (Outeiro and 
Lindquist, 2003; Dixon et al., 2005; Zabrocki et al., 2005). 
My thesis is divided into three studies in an 
attempt to understand three questions. What is the 
mechanism of -synuclein aggregation in vivo? How -
synuclein’s interactions with lipids influence -synuclein 
aggregation formation and cellular toxicity in vivo? How does 
oxidative stress contribute to -synuclein aggregate 
formation and toxicity? The following sections will provide 
the basis of my thesis studies, my aims and hypotheses, and 
explanation for the model organisms I use to carry out my 
research. 
 
Model organisms to study PD 
Saccharomyces cerevisiae (budding yeast) has emerged as 
a powerful genetic system to model protein misfolding-linked 
neurodegenerative diseases (Outeiro and Muchowski, 
2004), including prion diseases (Ma and Lindquist, 1999), 
Huntington’s disease (Krobitsch and Lindquist, 2000; 
Muchowski et al., 2002), and amyotrophic lateral sclerosis 
(Kunst et al., 1997). Using budding yeast models, properties 
of -synuclein protein in live cells are being uncovered. Wild-
type and A53T mutant -synuclein were found to associate 
with plasma membrane and aggregate within cells; whereas 
the A30P mutant neither localizes to the plasma membrane 
nor aggregates (Outeiro and Lindquist, 2003; Dixon et al., 
2005; Zabrocki et al., 2005; Sharma et al., 2006). However, 
-synuclein toxicity is not present independently in all of 
these budding yeast models. In fact, two models 
demonstrate that -synuclein aggregation itself causes 
toxicity (Outeiro and Lindquist, 2003; Dixon et al., 2005). The 
other two studies find that -synuclein-dependent toxicity 
requires an additional chemical or genetic insult, such as 
proteasomal inhibition and oxidative stress (Zabrocki et al., 
2005; Sharma et al., 2006) or coexpression of the 
microtubule-associated protein tau (Zabrocki et al., 2005). 
Overexpression of -synuclein in yeast can lead to abnormal 
lipid accumulation (Outeiro and Lindquist, 2003) and disrupt 
vesicle trafficking (Outeiro and Lindquist, 2003; Zabrocki et 
al., 2005). Further dissecting the unknown molecular 
pathway of pathogenic misfolded -synuclein, inhibition of 
phospholipid metabolism (Outeiro and Lindquist, 2003) and 
secretory pathway dysfunction (Dixon et al., 2005) can also 
increase -synuclein-dependent toxicity. In budding yeast, 
so far, there are 86 identified genes when absent with 
overexpressed -synuclein are synthetically lethal.  
I will also employ another family of yeast, 
Schizosaccharomyces pombe (fission yeast). The 
organism’s genome is sequenced which provides us an 
opportunity to do molecular biology work with it. In the past, 
fission yeast has provided insight into the mechanism of the 
cell cycle (Fantes and Beggs, 2000), DNA repair and 
recombination (Davis and Smith, 2001), and checkpoint 
controls needed for stability (Humphrey, 2000). Needless to 
say, fission yeast use as a model organism for protein 
misfolding neurodegenerative diseases, including PD, has 
been sparse. Similar to budding yeast, fission yeast share 
with humans a high conservation of protein folding, stress 
response, and protein quality control pathways (Wood et al. 
2002) making the organism a potential good model for PD 
neuron.  
 
Mechanism of -synuclein misfolding and aggregation 
The process of Lewy body formation from misfolded -
synuclein was first tested in in vitro experiments. Studies 
suggest that -synuclein aggregation follows a hypothetical 
model called nucleation polymerization (Conway et al., 
2000). Previously, misfolded protein aggregation in many 
neurodegenerative diseases, for instance, -amyloids in 
Alzheimer’s Disease, huntingtin in Huntington’s Disease, and 
prion proteins in Transmissible Spongiform 
Encephalopathies were predicted by this model (Caughey 
and Lansbury, 2003; Perutz and Windle, 2001). In essence, 
the model states that soluble protein monomers aggregate 
into polymers over time. The process is facilitated by the 
formation of a small oligomer that seeds the polymerization 
process (Figure 2A). Increasing the oligomerization of the 
protein (seeds) by increasing protein concentration facilitates 
faster rate of polymerization. Many in vitro studies observed 
the aggregation of wild type and familial mutant (A30P and 
A53T) forms of purified recombinant -synuclein follow this 
model (Conway et al., 1998, 2000; Giasson et al., 1999; 
Nahri et al., 1999; Wood et al., 1999; Li et al., 2001; 
Shtilerman et al., 2002). Though -synuclein fibril formation 
proposed by nucleation polymerization model has been 
extensively studied in vitro, evidence to support this model in 
vivo are still being conducted.  
The nucleation polymerization model proposes an 
explanation for how misfolded -synuclein aggregates into 
the amyloid fibrils similar to Lewy bodies in dying neurons of 
PD patients (Caughey and Lansbury, 2003). Only recently, 
fission yeast (Schizosaccharomyces pombe) was developed 
as a PD model organism to study -synuclein’s misfolding, 
aggregation, and cytotoxic properties (Brandis et al., 2006). 
In this in vivo study, cellular toxicity was absent, but -
synuclein formed aggregates extensively over time and 
concentration (see Appendix Figuire A.1.). This new study 
provides evidence for the in vivo support of nucleation 
polymerization model for -synuclein aggregation.  Two 
concentration levels (high and low) of the protein were 
expressed in the fission yeast (Figure 2B), but analysis with 
moderate expression of -synuclein was not conducted. 
Thereby, the results provided us with an incomplete picture 
for the support of the nucleation polymerization model. For 
my first thesis goal, I evaluated -synuclein misfolding, 
aggregation and toxic properties in fission yeast when the 
protein was expressed at moderate concentrations.   
 
-Synuclein interactions with lipid membranes  
Many studies have shown -synuclein to bind to 
phospholipids (Davidson et al., 1998; Jo et al. 2000; Eliezer 
et al. 2001; Dixon, et al. 2005; Kim et al. 2006; Rochet et al., 
2004) and, this interaction proves to be important in 
physiological functions such as neuronal plasticity (Lücking, 
and Brice, 2000; Clayton, and George 1999), neuronal 
differentiation (Lücking, and Brice, 2000; Kaplan et al., 2003) 
and secretion of neurotransmitters (Lücking, and Brice, 
2000; Fortin et al., 2005; Kaplan et al., 2003; Maroteaux et 
al., 1988). Though the biology of -synuclein interaction with 
lipids has been extensively elucidated with in vitro 
experiments, the in vivo consequences of such interaction in 
PD pathogenesis remain unclear. Close examination of -
synuclein membrane binding in vivo will help us elucidate the 
pathology of the protein in humans. 
In vitro evidence: In test tube studies, -synuclein 
is shown to exist in at least two structural forms. The free -
synuclein is largely unfolded in solution or cytosol, but goes 
through helical conformations upon binding to lipids (Eleizer 
et al., 2001). The binding is spontaneous driven by the 
charged lipid head groups (Kim et al., 2006). The cause of -
synuclein toxicity outside the living system has been 
investigated.  Volles et al. (2001) considered protofibrils, an 
-synuclein form between monomer and fibril to be 
neurotoxic. They bind more tightly to lipid membranes than 
the monomeric and fibrillar form of -synuclein (Volles et al., 
2001).  If protofibrils were present in the cells, the cellular 
environment probably would try to cope with protofibril 
toxicity by driving the protein to fibril form. Indeed, evidence 
of -synuclein fibril formation through protective cellular 
mechanism has been seen. In model systems of PD, -
synuclein fibrils form without associated toxicity (Rochet et 
al., 2000). But the protofibril membrane permeabilization 
activity could crucially account for the toxicity of -synuclein 
in PD (Scherzer and Feany, 2004; Conway et al., 2001).  
 
 
 
Figure 2. Hypothesis for misfolded a-synuclein aggregation in fission yeast. A. Illustration of the nucleation polymerization model. The process of 
polymerization for the protein starts as soluble monomer, changing to oligomer (seed) and then finally precipitating out of the solution as polymer. This 
process is time and concentration dependent (initial concentration on the red curve is higher in comparison to the black curve). B. Brandis et. al (2006) 
employ vectors to express a-synuclein in vivo at various concentration levels. Accordant with the nucleation polymerization hypothesis, a-synuclein 
aggregates increased as the protein concentration increased. No analysis was done where a-synuclein is moderately expressed.  
In vivo evidence: A correlation of -synuclein 
membrane binding with cellular toxicity exists (Dixon et al., 
2005; Chua and Tang, 2006; Cooper et al., 2006). Similar to 
binding of -synuclein to artificial phospholipid vesicles, -
synuclein’s lipid binding in the cells is mediated by -helix 
formation in the N-terminal repeat region (Kim et al., 2006). 
However, PD familial A30P mutation, but not A53T, reduces 
membrane binding. In contrast to in vitro study with artificial 
membranes, -synuclein interaction with biological 
membranes is rapidly reversible and is not driven by 
electrostatic attraction. Rather, -synuclein’s lipid binding 
demonstrates to be complex in live cells as it is not 
determined solely by intrinsic properties of the protein or the 
membranes (Kim et al., 2006).  
Using cell cultures and animal models of PD, 
possible pathological interaction between -synuclein and 
lipids has been linked more closely. Transgenic mouse 
model for PD shows that the -synuclein primarily localizes 
to highly lipid neuronal region of synaptosomes (Khale et al., 
2003). In the yeast Saccharomyces cerevisiae PD model, 
both the WT and the A53T isoforms of -synuclein localize to 
the plasma membrane (Dixon et al., 2005; Outeiro and 
Lindquist, 2003). They have been delivered to the 
membrane via the secretory pathway. In contrast, the A30P 
mutant protein disperses within the cytoplasm and has no 
binding with the plasma membrane. When their expression 
is elevated, WT and A53T, but not A30P, are toxic to cells. In 
this study, a direct relationship is present between plasma 
membrane localization of -synuclein and its toxicity in yeast 
(Dixon et al., 2005).  
Yeast continues to serve as a good model system 
for PD. A screen of several thousand library clones in yeast 
identified 25 non-toxic -synuclein sequence variants (Volles 
et al., 2007). Interestingly, these variants had a mutation to 
either proline or glutamic acid, which cause a defect in 
membrane binding. Based on these findings, it is possible 
yeast toxicity arise by -synuclein binding directly to 
membranes at levels sufficient to disrupt cell’s homeostasis 
(Volles et al., 2007).  
In our lab, we work with two yeast model 
organisms that express -synuclein. However, only budding 
yeast show -synuclein dependent toxicity (Sharma et al., 
2006). These cells also have localization of -synuclein to 
the plasma membrane. We speculate that the lack of 
membrane association in fission yeast may be due to 
changes in plasma membrane phospholipid composition. 
Budding and fission yeasts have slight different phospholipid 
composition, particularly phosphatidylethanolamine 
(Fernandez et al., 1986). In in vitro study, evidence of -
synuclein interaction with phospholipids is strong. The 
protein is known to interact with the phosphatidylinositol 
signaling pathway (Narayanan et al., 2005) and preferentially 
binds to acidic phospholipids such 
phosphatidylethanolamine (PE) and phosphatidylserine 
(PS); (Jo et al., 2000; Perrin et al., 2000).  
Both  in vitro and in vivo evidence give us clues 
about how might -synuclein, in lipid binding state, become 
toxic given that the pathological conditions exist (e.g. 
oxidative stress); (Figure 3). In living cells, -synuclein 
reversible lipid binding property can be altered to one which 
is irreversible when there is cellular oxidative stress. 
Dopaminergic neurons are possibly vulnerable to oxidative 
stress because dopamine quinones from the oxidation of 
dopamine stabilize lipid bound -synuclein species (Conway 
et al., 2001). 
We would like to determine whether the induction 
of phospholipids production directly correlates with the 
increase of -synuclein’s interaction with phospholipids and 
cellular toxicity. Secondly, we would like to determine which 
specific phospholipid(s) are possibly involved in -synuclein 
binding to the plasma membrane. If those phospholipid(s) 
are lost, would we observe reduction in -synuclein toxicity? 
Thus, in my second thesis goal, I investigated these 
questions in budding and fission yeast by genetically and 
chemically regulating the cellular phospholipid content.  
 
Oxidative Stress and PD 
Oxidative stress occurs largely due to mitochondrial 
dysfunction where stress is put on the cell by the production 
of reactive oxygen species (ROS) such as superoxide, 
hydrogen peroxide, and the hydroxyl radical (Abou-Sleiman 
et al., 2006). ROS within the cells can damage cellular 
structures which comprise of lipid membranes via lipid 
peroxidation (Giorgio Lenaz, 1998). ROS can also modulate 
important metabolic and other cellular activities by oxidizing 
critical proteins, and causing mutations in the mitochondrial 
DNA (mtDNA) (Alam et al, 1997). The inhibition of complex I 
of the mitochondria has been shown to generate ROS, which 
can damage the electron-transport chain and lead to the 
further production of ROS (Dauer, and Przedborski, 2003). 
In PD human brains and model organisms, several studies 
have confirmed the deficiency of complex I of the 
mitochondria (Parker 1989; Schapira, 1998; Simon et al., 
2000; Valente et al., 2004; Devi et al., 2008). Interestingly, 
the death of dopaminergic neurons has been shown to 
increase when complex I of the mitochondria is deficient 
(Kweon et al., 2004).  
Several PD inducing molecular species have been 
discovered which induce oxidative stress and lead to death 
of dopaminergic neurons. For example, the drug 1-methyl-4-
phenyl-1,2,3,4-tetrahydropyridine (MPTP) can cause 
extensive death of dopaminergic neuronal in the substantia 
nigra. This drug has been used to model PD in non-human 
primates (Burns et al., 1986), mice (Ogawa et al., 1985), rats 
(Saghal et al., 1984) and zebrafish (Bretaud et al., 2004) 
resulting in an acute and irreversible parkinsonian syndrome. 
When examined closely, the dose of MPTP inhibited function 
of complex I of the mitochondrial electron transport chain. 
Mitochondrial dysfunction was also exhibited in rat model for 
PD where the organism was exposed to rotenone, a specific 
mitochondrial complex I inhibitor. The exposure to rotenone 
brought about key features of PD, particularly the 
cytoplasmic, -synuclein fibrils (Dawson and Dawson, 2003). 
The role of oxidative stress in PD using yeast 
models appears to be promising. Recently, -synuclein’s 
toxicity can be enhanced with oxidative stress in budding 
yeast (Sharma et al., 2006). On the contrary, fission yeast 
model for PD can be robust when -is 
overexpressed (Brandis et al., 2006). Perhaps, additional 
stress on fission yeast is required for occurrence of -
synuclein cellular toxicity. The path to cellular toxicity might 
involve that both -synuclein expression and oxidant 
accumulation are present (Figure 4). Thus for my third thesis 
goal, I evaluate the toxicity of -synuclein in fission yeast 
when the organism exhibits oxidative stress. 
 
Hypotheses and Aims 
Study 1:  Hypothesis: -Synuclein misfolding and 
aggregation in live cells will follow the nucleation-
polymerization model. The aim of the first study was to 
moderately express -synuclein in fission yeast and 
compare -synuclein aggregation and toxicity with previously 
seen. I predicted that -synuclein would aggregate at an 
intermediate level and aggregates would appear later in time 
course than at higher concentration. Plus, these cells would 
not be toxic.  
Study 2:  Hypothesis: Increasing phospholipid 
association of -synuclein will enhance cellular toxicity of the 
protein. The aim was to increase (via DMSO treatment) or 
decrease (via deletion of a gene) cellular phospholipids and 
observe any difference in -synuclein’s localization and 
cellular toxic properties. I predicted that -synuclein in the 
budding yeast would localize more to the plasma membrane 
in the presence of DMSO compared to the control condition. 
In the fission yeast, I predicted that the chemical would 
decrease the formation of cytoplasmic aggregates and 
increase -synuclein’s plasma membrane localization. Also, 
both yeasts would incur cellular toxicity. 
Study 3:  Hypothesis: -Synuclein dependent 
toxicity will enhance in the presence of oxidative stress. The 
aim of this study was to evaluate the effects of -synuclein 
dependent toxicity in the presence of oxidative stress using 
fission yeast as a model organism. We added exogenous 
oxidant (hydrogen peroxide), and I predicted that -synuclein 
toxicity will enhance in a combinatorial manner with oxidative 
stress in fission yeast. Lastly, I predicted that -synuclein 
aggregates would be altered under oxidative stress.  
The next three sections will detail the materials 
and methods, results and discussion of the three studies—
Chapter 1: Live cell evidence of nucleation polymerization 
model of -synuclein misfolding and aggregation: 
Concentration Is Key; Chapter 2: Does cellular toxicity 
require -synuclein association with lipids?; Chapter 3: Does 
oxidative stress trigger cellular toxicity in -synuclein 
expressing fission yeast? 
 
 
 
Figure 3. a-Synuclein’s lipid binding properties. Could the way a-synuclein bind in living system under pathological condition like oxidative stress 
may provide clue to mechanism of a-synuclein dependent toxicity? Such cellular condition would contain free oxygen radicals. -Synuclein rapid 
dissociation from lipid membrane may be impacted. Though otherwise regulated step by the cellular components, the tight irregular lipid-binding of -
synuclein is hypothesized to cause damage to cells. Figure adapted from Kim, Y. S. et al (2006). 
 
 
 
Figure 4. Pathways for oxidative stress and a-synuclein cellular toxicity.  The independent pathways state that a-synuclein aggregation and 
oxidant accumulation are toxic to the cell via separate pathways. The combinatorial pathways proposes that a-synuclein misfolding may lead to oxidant 
accumulation, and oxidative stress may influence a-synuclein aggregation. Both outcomes perhaps together contribute to cellular toxicity.  
Materials and Methods 
 
S. Cerevisiae Expression Vectors 
The pYES2.1/V5-His-TOPO yeast expression vector 
(Invitrogen) was used for all -synuclein expression in 
budding yeast. The following three vector constructs were 
previously created for each experiment: green fluorescent 
protein (GFP), and wild-type -synuclein. -Synuclein was 
tagged at the C-terminus with GFP. For all experiments, the 
pYES2.1/V5-His-TOPO vector and the GFP tagged vector 
were used as expression controls (See Table 1 for List of 
Constructs) 
 
S. Pombe Expression Vectors 
Polymerase chain reaction (PCR) was used to amplify C-
terminal green fluorescence protein (GFP)-tagged -
synuclein (wild-type, A30P, A53T, A30P/A53T) fusion cDNA 
from the -sunclein-GFP containing pYES2/TOPO S. 
cerevisiae vectors constructed by Sharma et al.(2006): 
forward primer, 5'-
GGGGCCAAGCTTGCCATGGATGTATTCATGAAAGGA-3'; 
reverse primer, 5'-TTTGTAGAGCTCATACATGCCATG-3'. 
Similarly, PCR was used to amplify GFP cDNA from GFP-
pYES/TOPO S. cerevisiae vectors constructed by Sharma et 
al. (2006): forward primer, 
5'CCCGGGACCATGGCCAGCAAAGGAGAAG-3'; reverse 
primer, 5'-TTTGTAGAGCTCATACATGCCATG-3'.           
These PCR products were subcloned, according 
to the manufacturer’s protocol (Invitrogen), into each of 
these two fission yeast pNMT TOPO-TA expression vectors: 
pNMT1 (for high expression), and pNMT41 (for intermediate 
expression) vectors. The following three vector constructs 
were previously created for each experiment: green 
fluorescent protein (GFP), and wild-type -synuclein. -
Synuclein was tagged at the C-terminus with GFP. The 
pNMT-1/41 vectors and GFP in pNMT-1/41 vector served as 
expression controls (see Table 1 for List of Constructs). 
 
Yeast Strains 
The TCP1 strain (h-leu1-32; Invitrogen) of fission yeast was 
kindly provided by Judy Potashkin, Rosalind Franklin 
University of Medicine and Science. BY4741 (MATa his31 
leu20 met150 ura30) and CHO1 knockout strain were 
purchased from Open Biosystems. 
 
Yeast Transformation 
S. pombe strains were transformed with pNMT TOPO-TA 
vectors (Alfa et al., 1993) and S. Cerevisiae were 
transformed with pYES2.1/V5-His-TOPO vectors (see table 
1.) using the lithium-acetate transformation method (Burke et 
al., 2000). 
 
S. Pombe Expression 
For selection, yeast cells were grown on synthetic-complete 
media lacking leucine (PDM-leu). Presence of -synuclein 
constructs was confirmed by polymerase chain reaction 
(PCR). The pREP vector, containing a thiamine repressible 
promoter, allowed for regulated -synuclein expression. 
Yeast cells were first grown overnight in PDM-leucine (10uM 
thiamine) media at 30°C. Cells were washed with water and 
diluted to log-phase (5  10^6 cells/mL) in EMM lacking 
thiamine media to induce expression and grown to the time 
points desired for various measurements. 
 
S. Cerevisiae Expression 
For selection, yeast cells were grown on synthetic-complete 
media lacking uracil (SC-URA). Presence of -synuclein 
constructs was confirmed by polymerase chain reaction 
(PCR). The pYES2.1 vector, containing a galactose-
inducible promoter (GAL1), allowed for regulated -synuclein 
expression. Yeast cells were first grown overnight in SC-
URA glucose (2%) media at 30°C. Cells were washed with 
water and diluted to log-phase (5  10^6 cells/mL) in SC-
URA galactose (2%) media to induce expression and grown 
to the time points desired for various measurements. 
 
Fluorescence Microscopy  
Yeast cells were first grown overnight at 30
o
C in Edinburgh 
minimal medium (EMM) containing thiamine (10uM) if 
working with S. Pombe or in SC-URA glucose if working with 
S. Cerevisiae. After 24h, cells were pelleted at 1500g for 5 
minutes, washed twice in 10ml dH2O, resuspended in 10 ml 
EMM without thiamine/SC-URA galactose, of which 125 mL 
cells were used to inoculate 25 mL EMM without 
thiamine/SC-URA galactose (to express -synuclein). At 
desired expression time points for microscopy, cells were 
harvested at 1500g (4
o
C) for 5 min and were washed in 5 mL 
water. Then cells were resuspended in 100-1000 uL 
EMM+T/SC-URA glucose, of which 10 uL was pipetted onto 
a slide.  Slide of cell culture was viewed using Nikon TE-
2000U fluorescence microscope at 1000X magnification. 
Images were deconvoluted using MetaMorph software 
version 4.2. In order to quantify -synuclein aggregates, cells 
were first viewed under differential interference contrast 
(DIC) microscopy, and total cell count in the field was 
determined and viewed for GFP fluorescence. For analysis 
on S. Pombe, the number of cells in the field containing 1, 2, 
and 3+ aggregates or intracellular structure localization was 
determined. In case of analysis on S. Cerevisiae, the 
number of cells in the field which display halo, or aggregates 
(foci) was determined. The field was then moved three turns 
on the field control knob, and the process was repeated in a 
new field. At least 750 cells were evaluated for each 
treatment. Aggregates were scored as percent of total cells 
in the field that expressed 1, 2, and 3+ aggregates.     
 
Western Analyses 
Yeast cells (2.5x10
7
 cells/ml) were washed in 50 mM Tris 
(pH 7.5), 10 mM NaN3 and solubilized in Electrophoresis 
Sample Buffer (ESB; Burke, 2000) containing 2% sodium 
dodecyl sulfate (SDS), 80 mM Tris (Ph 6.8), 10% glycerol, 
1.5% dithiothreitol, 1 mg/ml bromophenol blue, and a 
cocktail of protease inhibitors and solubilizing agents (1% 
Triton-X 100, 1 mM phenylmethylsulfonyl fluoride, 1 mM 
benzamidine, 1 mM sodium orthovanadate, 0.7 mg/ml 
pepstatin A, 0.5 mg/ml leupeptin, 10 mg/ml E64, 2mg/ml 
aprotinin, and 2 mg/ml chymostatin).   Samples were run on 
pre-cast 10-20% Tris-Glycine gels (Invitrogen) using SDS 
containing running buffer. SeeBlue (Invitrogen) was  
used as the molecular standard. Gels were transferred to 
PVDF membranes and Western blot was performed. For 
analysis on S. Cerevisiae, anti-V5 AP monoclonal antibody 
and anti-PGK (Molecular Probes) for loading control was 
used. For S. Pombe, anti-V5 AP monoclonal antibody and 
anti-beta actin (Molecular Probes) for loading control was 
employed. The immunodetection protocol from Invitrogen 
Western Breeze kit was used to detect the alkaline 
phosphatase activity. 
 
Growth Curve 
Cells were grown in 5 ml PDM-Leu/SC-URA glucose 
overnight at 30
o
C in the incubator which rotates at 200 rpm. 
Cells were harvested at 1500 x g for 5 min at 4¢XC, and 
were washed twice in 5 ml H20. Cells were re-suspended in 
5 ml H20 and were counted. Flasks with 25 ml EMM/SC-URA 
galactose were each inoculated with 2.0x10
6
cells/ml density. 
At 0, 6, 12, 18, 24, 36 and 48 hours, and in duplicate 
measurements, 1 ml of cell culture was removed and placed 
in a cuvet to measure absorbance using a Hitachi U-2000 
Spectrophotometer. Averaged absorbance readings were 
plotted against time points to produce a growth curve.  
 
Spotting Analysis  
For spotting, cells were grown to mid-log phase in PDM-leu 
(S. Pombe) or in SC-URA glucose (2%) (S. Cerevisiae), 
normalized to equal densities (2  107 cells/mL), serially 
diluted (5-fold) into 96-well microwell plates. Using a multi-
channel pipettor, culture is spotted on EMM + thiamine or 
EMM – thiamine plates in the case when working with S. 
Pombe  and SC-URA glucose (2%) or galactose (2%) plates 
when working with S. Cerevisiae. Photographs were 
scanned after 2 d of growth. 
 
DMSO Treatment 
Dimethyl sulfoxide (DMSO) was purchased from Sigma-
Aldrich. Cells were grown in 10 ml PDM-leu (S. Pombe) or in 
SC-URA glucose (2%) (S. Cerevisiae) overnight at 30
o
C. 
Steps of cell harvesting and calculating cell density for 
inoculation was done according to the appropriate 
experiment. The cells which expressed -synuclein cloned in 
pNMT-1 vector were used when treating S. Pombe (TCP1) 
with DMSO. When treating S. Cerevisiae (BY4741) with 
DMSO, cell which expressed -synuclein in pYES2 vector 
were used. Before inoculation, DMSO was added in 
concentrations ranging from 0 to 10% in EMM media (S. 
Pombe) or in SC-URA galactose media (S. Cerevisiae). The 
concentration of DMSO exposure did not exceed 10%. A 
higher dose than 10% of DMSO would do harm to the cell 
(Zabrocki et al., 2005). After the DMSO mixed well in the 
inducing media, yeast cells were inoculated into it. Then the 
cells were observed at the desired time points for the 
following examinations: Western Analysis, Growth Curves, 
Spotting and Fluorescence Microscopy.     
Analysis on cho1 strain 
The deficiency in phospholipid content was produced using a 
knocked out yeast strain that lacks the gene CHO1 which 
encodes for phosphatidylserine synthase. The phospholipid 
biosynthetic pathway (see below; adapted Carman and 
Zeimetz, 1996) in yeast is a reference for understanding how 
specific phospholipid-deficient state is established. For this 
thesis, the main pathway of import is in blue and is termed 
the de novo pathway for synthesis of PS, PE and 
phosphotidycholine (PC). The purple pathways, called the 
Kennedy pathway are for using exogenous choline or 
ethanolamine to produce those phospholipids. The parent 
strain is BY4741. To stop PS production (it would still have 
all the rest of the phospholipids if ethanolamine present), we 
grew cho1 yeast strain in 1 mM ethanolamine in every 
selected media. Protocols written above for S. cerevisiae 
experiments such as growth curves, and live cell microscopy 
were followed. 
 
H2O2 treatment in S. Pombe 
Protocols written above for S. Pombe experiments such as 
growth curves, spotting and live cell microscopy were 
followed. H2O2 was added to the inducing liquid media EMM 
without thiamine or 25ml EMM agar plates (spotting 
analysis) to a final concentration of 0.4mM or 2mM. The 
control culture was cells untreated with H2O2. 
 
Statistical Analyses  
Statistical significance was established using a T-Test 
comparing the means of control cells containing no -
synuclein at 18 and 24 hours in treated versus untreated 
conditions.   
 
 
 
Phospholipid biosynthetic pathways in Saccharomyces cerevisiae. Reaction 3 in our study is terminated due to absence of PS synthase. The four 
major phospholipids (PC, PE, PI, and PS) are indicated by green boxes (Carman and Zeimetz, 1996). 
 Construct 
 
 
Expression Vector 
 
 
Strain 
 
 
Used in Chapter 1 Study 
 
 
No cDNA (parent plasmid) 
 
pNMT41 
 
TCP1 
GFP pNMT41 TCP1 
A30P -Synuclein-GFP pNMT41 TCP1 
A53T -Synuclein-GFP pNMT41 TCP1 
A30P/A53T -Synuclein-GFP 
 
pNMT41 
 
TCP1 
 
 
Used in Chapter 2 and 3 Studies 
 
 
No cDNA (parent plasmid) 
 
pNMT1 
 
TCP1 
GFP pNMT1 TCP1 
WT -Synuclein-GFP pNMT1 TCP1 
No cDNA (parent plasmid) pYES2.1 BY4741 
GFP pYES2.1 BY4741 
WT -Synuclein-GFP pYES2.1 BY4741 
No cDNA (parent plasmid) pYES2.1 cho1 
GFP pYES2.1 cho1 
WT -Synuclein-GFP pYES2.1 cho1 
   
 
Table 1. GFP-tagged -synuclein constructs created for thesis experiments. 
 
Chapter 1: Live cell evidence of nucleation 
polymerization model of -synuclein misfolding and 
aggregation: Concentration Is Key 
 
Results 
 
Moderately expressed -synuclein aggregates in live cells 
Our first goal was to moderately express -synuclein in 
fission yeast. Therefore, we used the PNMT-41 vector for -
synuclein expression, which was previously shown to 
achieve moderate expression by Western blot analysis 
(Brandis et al., 2006; see Appendix Figure A.1.). For this 
study, we used two familial mutants (A30P and A53T) 
because they localize differently under high expression in 
fission yeast: A30P remains cytoplasmically and A53T 
aggregates extensively (Brandis et al., 2006; see Appendix 
Figure A.1.). Using C-terminal GFP tagged -synuclein 
constructs, we then examined -synuclein localization in live 
cells by GFP microscopy. Time course microscopy revealed 
that A53T -synuclein formed aggregates as early as 18 
hour (Figure 5A). Quantification of aggregates confirmed this 
qualitative finding (Figure 5B). In contrast, A30P did not form 
aggregates and remained cytoplasmically throughout the 
time course. Interestingly, the double mutant A30P/A53T 
behaved similar to A30P indicating the dominance of A30P 
over A53T (Figure 5A). Therefore, under moderate 
expression, these three mutants achieve the same 
localization patterns, seen under high expression of -
synuclein (Brandis et al., 2006; Appendix Figure A.1). 
  
Moderately expressed -synuclein aggregates lesser and 
later  
Next, we compared the aggregation of A53T at high and 
moderate concentrations over a time course. Firstly, highly 
expressed -synuclein aggregates earlier than moderately 
expressed -synuclein (Figure 5C). Secondly at every point 
of the time course, highly expressed a-synuclein formed 
greater number of aggregates than moderately expressed 
synuclein (Figure 5C). This intermediate aggregates 
formation with moderately expressed -synuclein supports 
our initial hypothesis. 
 
Moderately expressed -synuclein is not toxic 
Our last goal was to examine toxicity of cells moderately 
expressing -synuclein. As expected, control cells containing 
just pNMT-1 grew healthy (Figure 5D). Cells expressing 
either A30P, A53T or A30P/A53T grew just as well as the 
control cells, demonstrating a lack of toxicity (Figure 5D). 
This lack of toxicity supports our initial hypothesis. 
 
 
 
Figure 5. Analysis of moderately expressed a-synuclein. A. -Synuclein was expressed in moderate concentration by pNMT41 promoter vector. 
These yeast were grown in EMM without thiamine. Images were captured at the indicated times over 36 hours for cells expressing A53T, A30P and 
A30P/A53T a-synuclein. B. Time course of quantified A53T -synuclein aggregation. Cells, cultured in EMM media without thiamine, expressed -
synuclein in moderate concentrations. The number of aggregates formed was was quantized in cells expressing A53T -synuclein over a 36-hr time 
course. Cells were scored in terms of containing 1 aggregate (blue bar), 2 aggregates (yellow bar), or 3 or more aggregates (red bar). Bars represent 
percentage of total cells counted in each sample that exhibited the designated number of aggregates per cell. C. Comparison of moderate to high 
expression of quantified A53T -synuclein aggregation. Comparison of quantified data on A53T -synuclein aggregates with high expression (blue bar) 
(Quantification data provided by Brandis et al. 2006) compared to moderate expression (green bar) over the 36-hr period. Bars represent percentage of 
total cells that had 1 or more aggregates per cell. D. Growth curve of cells moderately expressing a-synuclein. OD600 measurements were obtained 
over 48 hours for cells containing A30P, A53T, and A30/A53T forms of -synuclein in pNMT41 vector three separate times and averaged (n=3). Cells 
grown in thiamine (dashed lines) served as control.  
  
Discussion 
 
With the past study by Brandis et al. (2006) and this current 
study, we have now completed the successful development 
of a fission yeast as a model organism to study the 
misfolding, aggregation, and cytotoxic properties of -
synuclein linked to Parkinson's disease. Specifically, the 
work with fission yeast sheds provocative insight into the 
ideas that concentration of -synuclein is important for the 
protein’s aggregation and -synuclein aggregation may 
protect again cellular toxicity. 
 
-Synuclein aggregation: concentration is key 
Our first finding is that the protein’s polymerization activity is 
concentration dependent. At high concentrations, many -
synuclein aggregates are observed, while at low 
concentrations -synuclein aggregates are absent (Brandis 
et al, 2006). In the current study, at moderate concentration, 
-synuclein forms an intermediate number of aggregates. 
According to data by Brandis et al. (2006), the protein 
expression of moderate concentration was only slightly 
higher than the protein expression of the low concentration. 
The low concentration of -synuclein was not enough to lead 
to the formation of insoluble aggregates. Therefore, the 
evidence indicates that slightly higher (moderate) 
concentration of -synuclein is required to form aggregates. 
We consider the moderate concentration or a concentration 
near to it as the threshold point of -synuclein protein 
concentration that must be present to turn the soluble protein 
into insoluble aggregates. As protein concentration 
increases, the oligomers polymerize to form greater numbers 
of aggregates. Moreover, -synuclein aggregation activity is 
time-dependent. Overall, Brandis et al. (2006) and this study 
display both concentration and time-dependent -synuclein 
aggregation properties which support the grounds for the 
nucleation polymerization model in vivo. 
 
Toxicity: is membrane localization key?                            
Our second finding is that fission yeast presents itself as a 
robust organism despite the extensive formation of -
synuclein aggregates. To this date, in a fission yeast model, 
membrane localization of -synuclein has not been observed 
with cytotoxicity. In the budding yeast model, there is 
evidence of membrane localization with toxicity (Sharma et 
al., 2006). This leads to the hypothesis that membrane 
localization might be key to cytotoxicity.  We did not observe 
-synuclein dependent toxicity in fission yeast, but we still 
suspect that toxicity requires -synuclein membrane 
localization. In a previous study by Rochet et al. (2004), 
membrane localization of -synuclein was shown to be 
essential in creating toxic protofibrils. Under a different 
study, the destruction of vesicular membranes by 
protofibrillar -synuclein was directly observed by atomic 
force microscopy (Volles et al., 2001). In our lab, the toxicity 
of budding yeast was observed when -synuclein localized 
at the cell periphery. In budding yeast, the localization of -
synuclein to the plasma membrane happened prior to the 
formation of -synuclein aggregates. With the exception of 
A30P, wild-type and A53T -synuclein localized to the 
plasma membrane before forming inclusions (Sharma et al., 
2006). On the other hand, in our fission yeast model, neither 
toxicity nor membrane association was observed. Overall, a 
connection between -synuclein-dependent toxicity and a -
synuclein’s association with the plasma membrane is 
strongly implicated.  
 
Chapter 2: Does -synuclein binding to phospholipids 
regulate its toxicity? 
 
Results 
 
DMSO induces -synuclein independent toxicity in fission 
yeast 
Our first goal was to evaluate if a global induction of 
phospholipid synthesis would increase -synuclein-
dependent toxicity in fission yeast. We used a known 
phospholipid inducer in yeasts, the organic solvent DMSO 
(Murata et al., 2003). Toxicity was assessed in two ways. 
First, OD600 growth curves were performed on cells with or 
without a-synuclein and treated them with 0, 2, 5, and 10% 
DMSO. As previously reported (Brandis et al. 2006), wildtype 
-synuclein-GFP expressing cells that lacked DMSO grew 
well (Figure 6A). However, as DMSO concentration 
increased, and particularly at 10%, the growth curve shifted 
significantly to the right, indicating a toxic effect (Figure 6B-
C). Surprisingly, this toxicity was not -synuclein dependent, 
as it was seen even with cells that expressed GFP alone or 
only contained parent vector (Figure 6A-C). -Synuclein, at 
best, enhanced this DMSO toxicity by a very small margin 
(Figure 6C). Secondly, we evaluated colony survival on 
plates by serial dilution. Cell cultures either containing parent 
vector, GFP or, wild-type -synuclein serially diluted 5 times, 
were spotted onto sets of repressing (+thiamine) and 
inducing (-thiamine) plates, that contained 0, 2, 5, and 10% 
DMSO. Similar to growth curve analysis, we observed a 
striking dose-dependent toxicity with DMSO that was not 
dependent of the presence of a-synuclein (Figure 7).  
Together, both toxicity assays indicate that DMSO 
exerted an unexpected toxicity in fission yeast independent 
of -synuclein presence. 
 
DMSO alters -synuclein localization to internal structures in 
fission yeast 
Next, we evaluated if DMSO would induce any plasma 
membrane localization of -synuclein in fission yeast. -
synuclein localization was assessed by live cell GFP 
imaging. As previously reported (Brandis et al. 2006), 
wildtype -synuclein-GFP cells not treated with DMSO 
showed distinct cytoplasmic aggregates of -synuclein 
(Figure 8). DMSO treatment, at 5 and 10%, induced -
synuclein to alter its localization to internal cellular structures 
(Figure 8). Upon quantification, we determined that with 
increasing DMSO concentration, while -synuclein 
aggregates were still present, an increasing percent of cells 
began to display internal cellular structures (Figure 9).  
 
DMSO also induces -synuclein independent toxicity in 
budding yeast 
We conducted parallel studies in budding yeast using the 
strain BY4741 and asked if DMSO would increase -
synuclein-dependent toxicity. Again, we assessed toxicity in 
two ways. First, OD600 growth curves were performed on 
cells with or without -synuclein expression and treated them 
with 0, 2, 5, and 10% DMSO. Wildtype -synuclein-GFP 
expressing cells, independent of DMSO treatment, exhibited 
slight toxicity (Figure 10A). However, as DMSO 
concentration increased, and particularly at 10%, the growth 
curve shifted significantly to the right, indicating a toxic effect 
(Figure 10B-C). However, like seen with fission yeast, the 
toxicity was not specific to -synuclein. Cells that expressed 
GFP alone or only contained parent vector also exhibited 
similar magnitude of growth inhibition (Figure 10A-C). 
Secondly, we evaluated toxicity by spotting analysis. Cell 
cultures either containing parent vector, GFP or, wild-type -
synuclein were spotted onto sets of repressing (glucose) and 
inducing (galactose) plates, that contained 0, 2, 5, and 10% 
DMSO. Because this 10% DMSO toxicity was unexpected 
and contrary to published findings (Murata et al. 2003), we 
wondered if this DMSO toxicity was the result of the carbon 
source, galactose. But we found that 10% DMSO exhibited 
the same toxicity in cells grown on glucose (Figure 11A.) 
Lastly, we even considered that the toxic effect of DMSO 
possibly was peculiar to the BY4741 strain we had used. 
However, 10% DMSO demonstrated the same toxicity in a 
second yeast strain, TSY623 (Figure 11B). 
Similar to growth curve analysis, we observed a 
striking dose-dependent toxicity with DMSO that was not 
dependent of the presence of -synuclein (Figure 12). 
Together, both toxicity assays indicate that DMSO exerted 
an unexpected toxicity in budding yeast independent of -
synuclein presence. 
 
DMSO induces -synuclein aggregates and aberrant 
morphology  
Next, we evaluated if DMSO would induce additional plasma 
membrane localization of -synuclein in budding yeast. As 
previously reported (Sharma et al. 2006), untreated wildtype 
-synuclein-GFP cells showed -synuclein localizing to the 
plasma membrane. After these cells were treated with 
DMSO for 18 hour and 24 hour, GFP images were captured. 
At 5% DMSO, two major changes occurred: 1) Cells adopted 
aberrant morphology and they appeared elongated and 
sickle-shaped rather than as normal round shape; and 2) -
synuclein gained some intracellular localization that 
appeared like aggregates (Figure 13).  Quantification of 
cellular morphology indicated that the aberrant cellular 
morphology was highest at 5% DMSO treatment (Figure 14). 
Localization patterns indicated that in the normal shaped 
cells -synuclein primarily localized at the plasma 
membrane, while in the abnormal shaped cells, -synuclein 
significantly aggregated in the cytoplasm (Figure 15).  
 
 
Figure 6. Growth curves of fission yeast cells treated with DMSO.  Fission yeast cells were grown in EMM-T for 48 hours (x-axis) to induce parent 
pNMT-1 plasmid, GFP, and WT (wild-type) a-synuclein. Over this time course, the cells were treated with 2% (A), 5% (B) or 10% (C) DMSO (dashed 
lines) and compared to the cells that were not treated with DMSO (solid lines). Each of the points on the curves represents the mean from three trials 
on measurement of absorbance (y-axis). In addition, the standard error of the mean for a 95% confidence interval are represented by the y-bar on each 
of the points on the growth curves. Significant growth difference exists between pNMT-1 in 0% DMSO (n=3, P18hour= 0.007764 and P24hour= 
0.098409) and pNMT-1 in 10% DMSO.  
 
 
 
Figure 7. Serial Spotting of fission yeast cells treated with DMSO. Serially diluted cells expressing parent pNMT-1 plasmid, GFP, or WT a-
synuclein were spotted onto EMM+T (repressing) and EMM-T (inducing) plates. This experiment was repeated two separate times.  
 
 
Figure 8. Microscopy of fission yeast cells treated with DMSO.  Images were captured at 18 hour and 24 hour of induction in EMM-T. Aggregates 
(red arrow) in these cells started to form at 18 hour. With increasing concentrations of DMSO, a-synuclein began to localize to intracellular structures 
(purple arrow). 
 
 
Figure 9. Quantification of a-synuclein phenotypes in fission yeast cells. Cells expressing WT a-synuclein were counted and characterized by the 
following phenotypes: internal structure localization (blue bar), internal structure localization and aggregates (purple bar), or aggregates (yellow bar). 
Bars represent percent of 600-800 total cells which display those various a-synuclein phenotypes at different concentration of DMSO.  
 
 
Figure 10. Growth curves of BY4741 treated with DMSO.  BY4741 budding yeast cells were grown in Sc-ura galactose for 48 hours (x-axis) to 
induce parent pYES2 plasmid, GFP, and WT a-synuclein. Over this time course, the cells were treated with 2% (A), 5% (B) or 10% (C) DMSO (dashed 
lines) and compared to the cells that went without DMSO treatment (solid lines). Each of the points on the curves represents the mean from three trials 
on measurement of absorbances (y-axis). In addition, the standard error of the mean for a 95% confidence interval are represented by the y-bar on 
each of the points on the growth curves. Significant growth difference exists between pYES2 in 0% DMSO (n=3, P18hour= 0.00374 and P24hour= 
0.000497) and pYES2 in 10% DMSO.  
 
 
 
Figure 11. Growth curves in 10% DMSO of BY4741 (glucose control) and TSY623.  A. BY4741 budding yeast cells with parent plasmid were 
grown in Sc-ura galactose and glucose media to test if slow growth in 10% DMSO is partially due to change of sugar in the media. B. We tested 
another a-synuclein expressing budding yeast strain, TSY623, for its growth in 10% DMSO condition. Each of the points on the growth curves 
represents the mean from three trials. In addition, the standard error of the mean for a 95% confidence interval are represented by the y-bar on each of 
the points on the growth curves. 
 
 
Figure 12. Serial Spotting of BY4741 treated with DMSO. Serially diluted cells expressing parent pYES2 plasmid, GFP, or WT a-synuclein were 
spotted onto Sc-ura glucose (repressing) and Sc-ura galactose (inducing) plates. This experiment was repeated two separate times.  
 
 
 
Figure 13. Microscopy of BY4741 treated with DMSO.Images were captured at 18 hour of induction in Sc-ura galactose. Without DMSO treatment, 
most of the cells showed WT a-synuclein localized to the plasma membrane (halo) and GFP diffused in the cytoplasm. With increasing concentrations 
of DMSO, both GFP and WT cells showed aberrant morphology (red arrow). The aberrant morphological cells expressing wildtype a-synuclein showed 
increasing number of cytoplasmic a-synuclein aggregates (purple arrow).   
 
Figure 14. Quantification of cell morphology with DMSO treatment. DIC images of cells expressing WT a-synuclein were counted and 
characterized by those showing aberrant  morphology (blue bar) or normal oval shape (purple bar). Bars represent percent of 600-800 total cells which 
display those two different DIC images of the cells at various concentrations of DMSO. The appearance of aberrant morphology increased with higher 
concentration of DMSO and over time when quantifying cells at 18 hour versus 24 hour.  
 
Figure 15. Quantification of a-synuclein localization with DMSO treatment. Cells expressing WT a-synuclein were counted and quantified by those 
showing halo (blue bar), halo/aggregates (green bar), halo in aberrant yeast (red bar), halo/aggregates in aberrant yeast (sky blue bar) or foci in 
aberrant yeast (red bar). Bars represent percent of 600-800 total cells which display those various a-synuclein phenotypes at concentrations of 0%, 
2%, and 5% DMSO.  
 
 
Figure 16. Analysis of cho1 strain expressing a-synuclein. A. Microscopy of parent strain BY4741 and cho1 cells expressing WT a-synuclein. 
Images were captured at 24 and 36 hour of induction in Sc-Ura Galactose. In CHO1 knockout strain, the WT a-synuclein plasma membrane 
localization is intact similar to WT a-synuclein in parent strain. B. Growth curves of cho1 cells expressing isoforms of a-synuclein. No observable 
differences in growth exist between a-synuclein expressing cho1 cells and the cho1 controls, but significant growth difference exists between 
BY4741 (n=3, P18hour= 0.003636217and P24hour= 0.000723) and pYES2 in cho1 cells. Each of the points on the curves represents the mean from 
three trials on measurement of absorbances (y-axis). In addition, the standard error of the mean for a 95% confidence interval are represented by the 
y-bar on each of the points on the growth curves.  
 
Lack of phosphatidylserine makes yeast toxic 
Our third goal was to evaluate whether -synuclein 
association with plasma membrane was specific to a major 
membrane phospholipid. We began this analysis by asking 
whether a loss of a major phospholipid, phosphatidylserine 
(PS), from cellular membranes would change -synuclein 
toxicity in budding yeast. PS deficiency was achieved by 
using a yeast strain knocked out for the CHO1 gene (which 
codes for the enzyme phosphatidylserine synthase that 
synthesizes PS in budding yeast). Unfortunately, this 
knockout strain grew significantly slower than the wild-type 
strain BY4741 indicating a general toxicity making it difficult 
to assess -synuclein dependent effect (Figure 16B). When 
the cells finally started to grow, Cho1 strains expressing -
synuclein tagged GFP (wildtype, A30P, A53T, and E46K) 
exhibited similar growth curves compared to the controls 
cells (pYES2 and GFP; Figure 16A). 
 
Similar -synuclein localization pattern in cho1 yeast and 
BY4741 cells 
Nevertheless, we still evaluated -synuclein localization in 
surviving Cho1 cells by live cell GFP imaging to determine 
if the absence of PS altered membrane localization of -
synuclein. Both at 24 and 36 hours, Wild-type -synuclein 
localized to the plasma membrane in Cho1 and the parent 
BY4741 strain (Figure 16B), indicating that in these cells, -
synuclein associated with the plasma membrane without 
needing PS. 
 
Discussion 
 
We inquired about whether -synuclein’s association with 
phospholipid plasma membrane was critical to cellular 
toxicity and whether -synuclein’s membrane interaction was 
specific to certain phospholipids. Our first major finding is 
that DMSO exerted cellular toxicity independent of -
synuclein expression along with changing -synuclein’s 
phenotype and, specifically in budding yeast, changing 
cellular morphology. Our second major finding is that we 
found PS to be less critical to -synuclein’s phospholipid 
membrane binding.  
 
DMSO affects viability and influence aberrant cellular 
morphology 
The slow growth observed in both fission yeast and budding 
yeast was due to DMSO. Supporting evidence come from 
the growth curves of control cells, which expressed no -
synuclein and exhibited slow growth. Organic solvents, like 
DMSO, have been known to negatively affect the 
metabolism of microorganisms (Zhang et al., 2003). 
Previous finding on DMSO treatment to yeast showed that 
10% concentration in liquid media will reduce the density of 
the cell culture by half (Murata et al., 2003). In our study, 
during mid log phase (24hr), 10% DMSO media was shown 
to reduce the density of fission yeast cells by approximately 
half. Interestingly, same concentration of DMSO had a 
dramatic effect on the growth of the budding yeast cells 
which grew tenth of the density of cells untreated with 
DMSO. The chemical also induced budding yeast to have 
abnormal morphologies described in detail in the results 
section. These aberrant cell shapes were present starting at 
2% DMSO, and then higher at 5% DMSO. I predict that 
these cells are having difficulty dividing properly. They may 
have duplicated their DNA since the cell volume enlarged 
and appeared to be twice the size of normal yeast. Similar 
results have been observed with another haploid yeast 
Torulaspora delbrueckii that was induced into a diploid by 
treatment with DMSO (Sasaki and Ohshima, 1987). Indeed, 
DMSO affects the mammalian cell cycle too. The chemical 
inhibits the differentiation of myoblasts into muscle cells 
(Blau and Epstein, 1979) and the differentiation of the -
lymphocyte-derived cell line into IgM-producing cells. 
Besides the fact that DMSO is an inducer of cellular 
phospholipid, its influence may also be to disrupt cell cycle, 
as it may be exemplified in this study with yeast. 
 
DMSO increases -synuclein’s intracellular localization in 
fission yeast 
With increasing concentrations of DMSO, -synuclein level 
of toxicity was not enhanced. However, the expression of -
synuclein inside the cell became different. -Synuclein may 
have localized to the vacuolar membrane. FM4-64 dye, 
which is a vacuole stain, applied on fission yeast show 
vacuolar membrane structures (see image below). These 
intracellular structures resemble what -synuclein localized 
to in large number when the yeast cells were treated with 
DMSO. Though FM4-64 stain was not used in this thesis 
study, another yeast study by Pellens et al. (2005) showed 
colocalization of FM4-64 stained vacuoles with wild-type -
synuclein. Hence, we speculate that -synuclein possibly 
interactd ewith the vacuolar membranes in our fission yeast 
model. 
DMSO globally increases the phospholipids 
production in the cell (Murata et al., 2003). Besides the 
phospholipids in the plasma membrane, DMSO perhaps 
increased the interaction of -synuclein with phospholipids to 
other membrane bound organelles in the cell. In addition, the 
formation of -synuclein aggregates was also increased 
around the intracellular membranes. The lipid membrane 
interaction here demonstrates to be important for -synuclein 
aggregation, but it does not enhance -synuclein cellular 
toxicity. Toxicity and -synuclein’s plasma membrane 
localization are conceivably correlated, but these two events 
are still missing in our fission yeast model for PD and, as-yet 
they can not be discredited.   
 
DMSO also induces -synuclein localization in budding yeast  
-Synuclein is slightly toxic to the BY4741 budding yeast 
strain. Increasing DMSO concentration did not cause further 
-synuclein dependent toxicity. Moreover, the localization of 
the protein toward the plasma membrane was diminished 
with higher DMSO concentrations. We predicted that -
synuclein in budding yeast would localize more to the 
plasma membrane. Surprisingly, the protein formed non-
toxic aggregates in the cytoplasm when treated with 5% and 
10% DMSO. Our predictions are not well supported by these 
findings.  
 
 
 
imbs.massey.ac.nz/Hyamslab/fission.htm 
There are two views on how DMSO may have 
increased -synuclein aggregation in the cytoplasm. First, 
the chemical has global effects on lipid biosynthesis, as half 
of the genes in the ergosterol, sphingoglycolipid and fatty 
acid biosynthetic pathways are down-regulated (Zhang et al., 
2003). So, the down regulation may impact -synuclein lipid 
interaction in yeast because the protein has been shown to 
bind to those fatty acids and phospholipids (Sharon et al., 
2001; Kaplan et al., 2003; Salem et al., 2007; Davidson et 
al., 1998; Jo et al., 2000). Overall, we speculate that high 
concentration of DMSO (5-10%) reduces some of the 
phospholipids and fatty acids from the yeast plasma 
membrane and weaken -synuclein interaction with the 
plasma membrane structure. In effect, the reduced 
membrane binding of the -synuclein would result in a higher 
cytosolic concentration of -synuclein, leading to -synuclein 
aggregate formation.  
The alternative view is that the DMSO up-
regulates various groups of lipids particularly phospholipids. 
Genes such as INO1 and OPI3 in yeast, encoding key 
enzymes in phospholipid biosynthesis, are significantly 
elevated with DMSO treatment (Murata et. al., 2003). 
Because -synuclein has shown to preferentially bind to 
other phospholipids such as PI and PE in vitro (Jo et al., 
2000), -synuclein’s interaction with the plasma membrane 
maybe induced and in the process form lipid-bound 
aggregates (Lee et al., 2002; Sharma et al., 2006). However, 
under cellular context, -synuclein membrane association is 
different from test tube condition. In cells, the lipid binding is 
rapidly reversible (Fortin et al., 2005). Therefore, it is 
possible that aggregates are formed with increase of -
synuclein interaction with membranes as the DMSO 
concentration increases in yeast (Pellens et al., 2005). 
Subsequently, -synuclein’s interaction with the plasma 
membrane weakens and results in higher cytoplasmic 
aggregates. 
 
Does -synuclein bind to non-PS phospholipids? 
There exist four major cellular phospholipids: PC, PE, 
phosphatidylinositol (PI), and PS. We only analyzed one 
knockout strain that lacks phosphatidylserine synthase which 
makes PS. In the budding yeast model for PD, -synuclein’s 
localization to the plasma membrane is a prominent feature. 
In this current study, the localization to the plasma 
membrane was not lost as PS was lost from the cellular 
phospholipid membranes. We expected some if not all the 
reduction of -synuclein’s membrane localization. In in vitro, 
-synuclein is found to bind weakly to PS. The protein’s 
phospholipid affinity is higher with other phospholipids (Jo et 
al., 2000). This may explain why the protein remained 
localized to the plasma membrane in the yeast knockout 
strain because perhaps the protein’s lipid binding is not 
specific to PS. On the other hand, it is also possible that the 
interaction of -synuclein with PS is strong; no in vivo 
evidence is present to refute it otherwise. In this case, -
synuclein may have begun to interact with other 
phospholipids in the absence of PS.  
Also, the growth of the knockout yeast in inducing 
galactose media was drastically slowed in comparison to 
BY4741 parent strain. Usually when yeast’s sugar is 
changed from glucose to galactose, they grow slower, but 
the slow growth of knockout strain indicated to us that PS is 
an important major phospholipid in yeast. Evidently with 
these sick cells, it also meant that I could not get a 
dependable measurement on the level of toxicity of -
synuclein expression.  
 
Chapter 3: Does oxidative stress enhances -
synuclein’s toxicity in fission yeast? 
 
Results 
 
H2O2 induces -synuclein independent toxicity in fission 
yeast 
Our first goal was to evaluate how -synuclein dependent 
toxicity can increase in fission yeast. -Synuclein has 
minimal toxic effect in fission yeast. Though extensive -
synuclein aggregates formulated, the fission yeast remains 
robust (Brandis et al., 2006). H2O2 perhaps will function as 
an additional insult on the existing stress of -synuclein 
expression (Manning-Bog et al., 2002; Abou-Sleiman et al., 
2006). Eventually, the treatment could enhance -synuclein 
dependent toxicity. We treated the cells with various 
concentrations of H2O2. However, as H2O2 concentration 
increased, and particularly at 2mM, the growth curve shifted 
to the right, indicating a slight toxic effect (Figure 17A-B). 
Surprisingly, this toxicity was not -synuclein dependent, as 
it was seen even with cells that expressed GFP alone or only 
contained parent vector (Figure 17A-B). Secondly, we 
evaluated colony survival on plates by serial dilution. Cell 
cultures either containing parent vector, GFP or, wild-type -
synuclein serially diluted 5 times, were spotted onto sets of 
repressing (+thiamine) and inducing (-thiamine) plates, that 
contained 0, 0.4mM and 2mM H2O2. Similar to growth curve 
analysis, we observed a striking dose-dependent toxicity 
with H2O2 that was not dependent on the presence of -
synuclein (Figure 18).  
Together, both toxicity assays indicate that at 
2mM concentration H2O2 exerted an unexpected toxicity in 
fission yeast independent of -synuclein presence. 
 
 
 
Figure 17. Growth curves of fission yeast cells treated with H2O2. Fission yeast cells were grown in EMM-T for 48 hours (x-axis) 
to induce parent pNMT-1 plasmid, GFP, and WT a-synuclein. Over this time course, the cells were treated with 0.4mM(A), or 2mM 
(B) H2O2 (dashed lines) and compared to the cells that were not treated with H2O2 (solid lines). Each of the points on the curves 
represents the mean from two trials on measurement of absorbances (y-axis); (n=2, P18hour=0.002008 and P24hour= 0.017602 
between pNMT-1 in 0mM H2O2 and pNMT-1 in 2mM H2O2) 
 
 
Figure 18. Serial Spotting of fission yeast cells treated with H2O2. Serially diluted cells expressing parent pYES2 plasmid, GFP, or WT a-synuclein 
were spotted onto EMM+T (repressing) and EMM-T (inducing) plates. This experiment was repeated two separate times.  
 
 
 
Figure 19. Microscopy and quantification of a-synuclein phenotypes in fission treated with H2O2. Images were captured at 18 hour of induction 
in EMM-T (A). Aggregates were noticeable with treatment of H2O2, along with small percent of cells showing a-synuclein localizing to intracellular 
structures. Aggregate formation and localization to intracellular structures did not increase with higher dose of H2O2 treatment (B). Cells expressing 
WT a-synuclein were counted and characterized by those showing intracellular structure localization (blue bar), intracellular structure localization and 
aggregates (purple bar), or aggregates (yellow bar). Bars represent percent of 600-800 total cells which display those various a-synuclein phenotypes 
at different concentration of H2O2.  
H2O2 induces alteration of -synuclein localization to internal 
structures  
Next, we examined the phenotype of -synuclein in the 
fission yeast to determine whether -synuclein localization 
changed from aggregates. Images for cells expressing -
synuclein were taken at 18 hour post-induction. As the 
concentration of H2O2 was increased to 2mM, the 
predominant phenotype was aggregates. The lesser 
common phenotype was the localization of the protein into 
internal cellular structures. In fact, some cells had both of 
these -synuclein localization patterns (Figure 19A). 
Quantification indicated that majority of cells had -synuclein 
aggregates, meanwhile, greater percent of cells began to 
show both -synuclein intracellular localization and 
aggregates with increasing H2O2 concentrations (Figure 
19B).  
 
Discussion 
 
There is increasing evidence that oxidative stress is involved 
in Parkinson’s disease. Yet, a connection between -
synuclein misfolding and oxidative stress is not fully 
understood. Examined initially by Brandis et al. (2006), our 
fission model organism does not exhibit toxicity when -
synuclein is overexpressed. We inquired whether additional 
stress (e.g. oxidative) on fission yeast is critical for toxicity to 
occur. Our major finding is that H2O2 exerted toxicity on 
fission yeast surprisingly at low concentration, independent 
of -synuclein expression along with altering slightly -
synuclein’s phenotype. 
 
No enhancement of -synuclein toxicity with H2O2 treatment 
H2O2 is a powerful oxidizing agent, but its interaction with -
synuclein inside the cell may not be enough to cause -
synuclein dependent cell death. Additional cellular 
dysfunctions maybe required to occur before -synuclein 
dependent toxicity elevates. We presume that there are 
protective measures in fission yeast to suppress -synuclein 
toxicity. For example, anti-oxidant gene sod2 was shown to 
protect -synuclein toxicity in yeast cells (Willingham et al., 
2003). When the gene is deleted, -synuclein toxicity was 
exhibited and further enhanced with H2O2 treatment (Brandis 
et al., 2006). Perhaps certain gene(s) are responsible for 
regulating -synuclein toxicity in fission yeast, especially 
under oxidative stress.  
 
H2O2 toxicity in yeast 
The slow growth of fission yeast in media containing 2mM 
H2O2 was a surprising finding when we measured toxicity. 
On the contrary, the 2mM H2O2 does not impair growth of 
budding yeast (Sharma et al., 2006). In fact, the lethal dose 
is significantly higher and closer to 15-25mM in most 
budding yeast strains (McEwen et al., 1984).  Though fission 
yeast must be producing antioxidants and enzymes to break 
down reactive oxygen species generated by H2O2, they 
might not be adequate to maintain cellular redox 
homeostasis as the concentration rises to 2mM (Chen et al., 
2003). One study points out that a 2mM H2O2 concentration 
inhibits the fission yeast cell growth by 58% (Pekmez et al., 
2008). Also, the increased H2O2 concentrations lower the 
Glutathione (GSH) levels; 2.0 mM H2O2 treatment showed 
significant decrease in GSH level in fission yeast (Pekmez et 
al., 2008). GSH is an abundant thiol which has been shown 
to protect against the deleterious effects of reactive oxygen 
species in budding yeast cells (Grant et al., 1998). GSH 
expression in budding yeast and fission yeast may perhaps 
be different hence leading to difference in tolerance for H2O2 
treatment. Along with GSH, there might be group other 
regulatory genes in response to oxidative stress that may be 
responsible for why fission are sensitive to H2O2 treatment.  
Conclusion 
 
Using budding and fission yeast models of Parkinson’s 
disease, we have evaluated factors, protein concentration, 
phospholipids, and oxidants that can potentially regulate -
synuclein’s cellular toxicity. In the process, we have 
discovered that though these factors may not induce -
synuclein’s cellular toxicity, they can alter -synuclein’s 
localization inside the cell. In addition, to our surprise, 
chemical such DMSO can alter the morphology of budding 
yeast cells. 
 Currently, our major conception from current, and 
including previous, findings in vitro and in vivo studies 
suggest that -synuclein-dependent toxicity is better 
correlated with plasma membrane localization, rather than 
with intracellular aggregation. We are inching toward 
understanding -synuclein’s mode of toxicity. Willingham et 
al. (2003) conducted a yeast genetic screen and found that 
several membrane transport and lipid metabolism proteins 
regulated -synuclein’s toxicity.  
We do not think that fission yeast is a robust 
organism as we once thought. The slight increase in H2O2 in 
media was toxic to these yeasts. Perhaps, -synuclein is 
toxic to fission yeast, but in what form and with what 
molecules it associates that trigger its toxicity are yet to be 
resolved. Some -synuclein expressing fission yeast might 
be so toxic that they die early in the time course. We only 
microscopically observe these cells 18-48 hour -synuclein 
post-induction. Interestingly, during this time period, the cells 
appear to be non-toxic despite the extensive formation of 
aggregates. Similarly, PD patient’s brain when examined 
during autopsy consists of -synuclein aggregation within the 
substantia nigral neurons. These aggregates may perhaps 
be forming in a nucleation-polymerization dependent manner 
provided by the evidence we have contributed in this thesis. 
At the same time, there has been a significant decrease in 
the number of substantia nigral neurons. The neurons which 
persisted longer in this progressive neurodegenerative 
disease—available during autopsy—yield -synuclein in 
Lewy Bodies (Spillantini et al., 1998). It is possible that -
synuclein aggregates are ultimately neuroprotective where 
the cells are trying to sequester the protein all together and 
make misfolded -synuclein a better cellular target for 
degradation.    
 
Criticisms and Limitations 
DMSO was widely used in this study, but how the chemical 
induced change in cellular phospholipid biosynthesis in our 
yeasts is unclear. Up to date, we are the first to analyze the 
effects of DMSO on fission yeast. Plus, the effects of the 
chemical on budding yeast have varied, where one study 
analyzed it to be an up-regulator of phospholipids and fatty 
acids and another study finds it to be a down-regulator of 
phospholipids and fatty acids. DiOC6 is a commercially 
available dye that we have not employed but can use to 
detect changes in cellular phospholipids. In our fission yeast 
cells treated with DMSO, we observed -synuclein localizing 
to different places inside the cells, possibly membrane 
bound organelles like vacuoles. -Synuclein vacuolar 
localization remains unconfirmed because we have not 
shown this specific -synuclein localization with any 
fluorescent marker or stain. 
Lastly, there are inconsistencies between the 
results from growth curves and spotting analyses in our 
second study and third study of this thesis. Wild-type -
synuclein expressing fission yeast grew better in liquid 
media than on spotting agar plates. In budding yeast, wild-
type -synuclein grew slower in liquid media than on spotting 
agar plates. Investigation in the third study reflected similar 
problems. The addition of moderate 0.4mM H2O2 
concentration did not reduce cell growth in liquid media, but 
it did on agar plates irrespective of whether the cells 
expressed -synuclein. Overall, we think that more reliable 
results come from the growth curve analyses because first, 
they have been repeated more times than spotting, and 
second, in growth curve analyses, the cell culture is 
suspended in liquid media that is considerably homogenous. 
 
Future Research 
In the immediate future, we plan to do staining with -
synuclein expressing yeast cells that go through DMSO 
treatment. With DiOC6, we will be able to see possible 
changes in the cellular phospholipids. We will possibly use 
FM4-64 dye on DMSO treated fission yeast cells to stain 
vacuoles. The finding from the stain will be able to 
substantiate or refute our observation that DMSO induces -
synuclein to interact with vacoular membrane structures. In 
our third study, we discerned that fission yeast cells at 2mM 
H2O2 are dying in response to oxidative stress by the 
treatment of H2O2. Commercially available FUN stain will be 
a useful method to measure the rise of reactive oxygen 
species in the cell as the growth of fission yeast succumb to 
H2O2 treatment. For our further future investigations, we will 
explore some of the following questions: why -synuclein 
does not go to the plasma membrane in fission yeast and be 
a non-toxic cytoplasmic aggregate; are other major 
membrane phospholipids such PE, PI, and PC critical to -
synuclein membrane localization and toxicity. 
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